Pharma stocks to benefit after FM announces medicine tariff changes in Union Budget 2025 Pharma stocks to benefit after FM announces medicine tariff changes in Union Budget 2025 

Pharma stocks are set to benefit after the Finance Minister’s announcement of significant tariff changes. The government has added six life-saving medicines to the 5% concessional duty slab, improving access to essential drugs.

Additionally, full exemptions and concessional duties will apply to specific bulk drugs, further reducing costs. These measures are aimed at enhancing affordability and are expected to support the growth of the pharmaceutical sector.

Lupin Ltd: 

On February 1, 2025, Lupin Ltd (BSE: LUPIN) opened at ₹2,080.00, reached a high of ₹2,111.50, and a low of ₹2,030.65. The stock is currently trading at ₹2,067.30, down 0.65%, with a market cap of ₹94,317.37 Cr.

Lupin Ltd is a global pharmaceutical company known for its focus on generic medicines and active pharmaceutical ingredients. It has a diverse product portfolio spanning various therapeutic areas, including cardiovascular and central nervous system treatments. 

Also Read: Fertilizer and agriculture stocks to benefit after FM announces to boost the sector in union budget 2025

Sun Pharmaceutical Industries Ltd: 

On February 1, 2025, Sun Pharmaceutical Industries Ltd (BSE: SUNPHARMA) opened at ₹1,749.95, reached a high of ₹1,789.50, and a low of ₹1,743.95. The stock is currently trading at ₹1,755.95, up 0.74%, with a market cap of ₹4,21,300.93 Cr.

Sun Pharmaceutical Industries Ltd is one of the largest pharmaceutical companies in India, specialising in generic formulations and active pharmaceutical ingredients. It operates globally, with a strong presence in emerging and developed markets. 

Cipla Ltd: 

On February 1, 2025, Cipla Ltd (BSE: CIPLA) opened at ₹1,483.95, reached a high of ₹1,488.35, and a low of ₹1,427.25. The stock is currently trading at ₹1,438.25, down 2.78%, with a market cap of ₹1,16,155.09 Cr.

Cipla Ltd is a leading pharmaceutical company that manufactures a wide range of medicines, including generics and over-the-counter products. The company has a global footprint, focusing on treatments for respiratory, cardiovascular, and HIV/AIDS-related conditions.

Also Read: What are the development plans made by FM for Bihar in the union budget 2025?

Aurobindo Pharma Ltd: 

On February 1, 2025, Aurobindo Pharma Ltd (BSE: AUROPHARMA) opened at ₹1,195.20, reached a high of ₹1,195.20, and a low of ₹1,137.50. The stock is currently trading at ₹1,156.05, down 1.34%, with a market cap of ₹67,143.57 Cr.

Aurobindo Pharma Ltd is a major global pharmaceutical industry player known for its generic formulations and active pharmaceutical ingredients. The company has a strong presence in the U.S., Europe, and emerging markets. 

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.